Status:
COMPLETED
Validate the Safety and Feasibility of the CT-guided Interventional Robot in Percutaneous Biopsy Procedure.
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Collaborating Sponsors:
Tongji Hospital
The First Affiliated Hospital of Guangzhou Medical University
Conditions:
Abdominal Cancer
Thoracic Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This multicenter, randomized controlled trial aims to investigate whether the interventional robot can be well and safely used for percutaneous needle biopsy compared with the freehand needle biopsy m...
Detailed Description
Cancer has become the second main death reason among Chinese residents. According to the latest global cancer burden data for 2020 released by the International Agency for Research on Cancer (IARC) of...
Eligibility Criteria
Inclusion
- Participants have suspected thoracic or abdomen lesions.
- Participants need to receive CT-guided non-vascular percutaneous biopsy procedure
- Lesion size ≥ 10 mm that confirmed by radiologists through the preoperative CT.
Exclusion
- Participants with uncorrectable coagulopathy, infectious lesions in the planned needle trajectory path, pulmonary echinococcosis considered on CT imaging, patients who need mechanical ventilation, hepatic alveolar echinococcosis, coma or other diseases that the investigators think not suitable for joining the study.
Key Trial Info
Start Date :
July 3 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 24 2023
Estimated Enrollment :
166 Patients enrolled
Trial Details
Trial ID
NCT06484764
Start Date
July 3 2023
End Date
November 24 2023
Last Update
July 5 2024
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
First Clinical Affiliation of Guangzhou Medical University
Guangzhou, China
2
Tianjin Medical University Cancer Institute and Hospital
Tianjin, China
3
Tongji Hospital of Huazhong University of Science and Technology
Wuhan, China